EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies

Roko Šantić iD, Lovre Martinović, Nikola Pavlović iD, Doris Rušić iD, Marko Kumrić iD, Dinko Martinović iD, Tina Tičinović Kurir iD, Joško Božić iD

Metabolites · 27.05.2026 · 16 (6) · 364

DOI: 10.3390/metabo16060364 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 27.05.2026. Verfasst von Roko Šantić und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: GLP-1-based obesity pharmacotherapy has shifted clinical attention from the magnitude of weight loss to the quality of weight loss. This review evaluates whether body composition changes during treatment with GLP-1-based agents represent clinically meaningful muscle loss and identifies nutrition, supplementation, exercise, and monitoring strategies that may help preserve lean mass, function, bone health, and nutritional adequacy.

Methods

A comprehensive narrative review was performed using focused searches of PubMed, publisher-hosted journal platforms, and reference lists of key primary studies and recent evidence syntheses through March and May 2026. Evidence was organized around body composition, muscle quality and function, dietary protein and micronutrient adequacy, exercise, supplementation, bioelectrical impedance analysis, imaging, and emerging biomarkers.

Results

Semaglutide and tirzepatide preferentially reduce fat mass, including visceral and ectopic adiposity, while producing smaller but consistent reductions in lean mass or lean soft tissue. However, DXA-derived lean mass and BIA-derived fat-free mass are not equivalent to skeletal muscle, and lean tissue loss does not necessarily indicate impaired strength or physical performance. The most defensible supportive care model combines food-first nutritional counseling, adequate protein intake, structured resistance exercise, management of gastrointestinal adverse effects, and risk-based monitoring of micronutrient inadequacy. Protein supplementation and nutritionally complete meal replacements may be useful when intake is insufficient, whereas creatine, essential amino acids or leucine, beta-hydroxy-beta-methylbutyrate, fiber, probiotics, omega-3 fatty acids, and multi-ingredient products remain adjunctive options supported mainly by indirect or phenotype-specific evidence.

Conclusions

Future GLP-1 trials and clinical care should move beyond body weight and total lean mass toward integrated assessment of muscle quantity, muscle quality, function, bone, and nutritional adequacy, and standardized BIA-based clinical monitoring where advanced imaging is not feasible.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistsbioelectrical impedance analysisdietary supplementationobesityprotein intakesemaglutideskeletal muscle masstirzepatide

Autor:innen und Institutionen

  • Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.
  • Laboratory for Cardiometabolic Research, University of Split School of Medicine, Soltanska 2A, 21000 Split, Croatia.
  • Department of Pharmacy, University of Split School of Medicine, Soltanska 2A, 21000 Split, Croatia.
  • Department of Maxillofacial Surgery, University Hospital of Split, Spinciceva 1, 21000 Split, Croatia.
  • Department of Maxillofacial Surgery, University of Split School of Medicine, 21000 Split, Croatia.
  • Department of Endocrinology, Diabetes and Metabolic Diseases, University Hospital of Split, Spinciceva 1, 21000 Split, Croatia.

ORCID-Profile: Roko Šantić, Nikola Pavlović, Doris Rušić, Marko Kumrić, Dinko Martinović, Tina Tičinović Kurir, Joško Božić

Zitieren

APA

Šantić, R., Martinović, L., Pavlović, N., Rušić, D., Kumrić, M., Martinović, D., Tičinović Kurir, T., & Božić, J. (2026). Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. Metabolites, 16(6), 364. https://doi.org/10.3390/metabo16060364

Vancouver

Šantić R, Martinović L, Pavlović N, Rušić D, Kumrić M, Martinović D, et al. Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. Metabolites. 2026;16(6):364. doi:10.3390/metabo16060364

BibTeX
@article{anti2026,
  author = {Šantić, Roko and Martinović, Lovre and Pavlović, Nikola and Rušić, Doris and Kumrić, Marko and Martinović, Dinko and Tičinović Kurir, Tina and Božić, Joško},
  title = {Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies},
  journal = {Metabolites},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {364},
  doi = {10.3390/metabo16060364}
}
Kostenlos starten →